Quality of interaction database management systems

Rodríguez-Terol, A.; Caraballo, M.O.; Palma, D.; Santos-Ramos, B.; Molina, T.; Desongles, T.; Aguilar, A.

doi:10.1016/S2173-5085(09)70079-6

Article information

Statistics

Abstract

Objective

To identify drug interaction databases (DID) and assess the quality of their structures.

Method

A search was made of the literature for DID and a series of exclusion and structural quality criteria were defined (at least 4 quality criteria: classification according to severity, classification according to level of evidence, bibliographical reference data, description of clinical management, and 11 criteria used for weighting). The level of compliance of every DID with the criteria defined was analysed, together with the level of compliance of each criteria in each DID.

Results

A total of 54 DID were identified, 30 of which complied with exclusion criteria and 15 of which did not meet the minimum criteria. The rest of the criteria were evaluated in 9 DID: Botplus and Medinteract (100%), SEFH Guide, Lexi-interact and Medscape (89%), Hansten (83%), Micromedex and Stockley (78%), Drug Interactions Facts (68%). Ninety-two percent of the DID describe the mechanism of action, 87% classify the information according to the active ingredient, 75% do not state they have any conflict of interest, classify according to level of severity, have electronic format, and are easy to search. A total of 67% are specific DID, 62% are classified according to level of evidence, contain bibliographical references, and describe clinical management.

Conclusions

A third of the DID comply with the minimum criteria. Differences were observed in the level and compliance criteria among Spanish and foreign DID. Some of the main DID used as references in the bibliography have significant structural defects: no web presentation, no multi-check function and others.

Key words:

Drug interaction

Database management systems

Quality assurance

Resumen

Objetivo

Identificar bases de datos de interacciones medicamentosas (BDIM) y valorar su calidad estructural.

Método

Se realizó una búsqueda bibliográfica de BDIM y una definición de criterios de exclusión y calidad estructural (4 criterios de calidad mínima: estratificación según grado de gravedad, clasificación según nivel de evidencia, referencia bibliográfica de datos, descripción del manejo clínico, y 11 criterios que aportaban peso ponderal). Se analizó el grado de cumplimiento en cada BDIM de los criterios definidos y el grado de cumplimiento de cada criterio en todas las BDIM.

Resultados

Se identificaron 54 BDIM de las que 30 cumplían criterios de exclusión y 15 no reunían criterios mínimos. Se valoró el resto de los criterios en 9 BSM: Bot-plus y Medinteract (100%), Guía de la SEFH, Lexi-interact y Medscape (89%), Hansten (83%), Micromedex y Stockley (78%), Drug Interactions Facts (68%). El 92% de las BDIM describen mecanismo de acción, el 87% estructura la información por principio activo, el 75% no declara tener conflicto de intereses, estratifica según grado de gravedad, tiene soporte informático y la búsqueda es ágil. El 67% son BDIM específicas, el 62% clasifica según nivel de evidencia, contiene referencias bibliográficas y describe el manejo clínico.

Conclusiones

Un tercio de las BDIM cumplen criterios mínimos. Se encontraron diferencias en el grado y el criterio de cumplimiento entre las BDIM españolas y las de otros países. Algunas de las principales BDIM utilizadas como referentes en la bibliografía presentan importantes deficiencias estructurales: la falta de presentación web y de función multi-check y otras.

Palabras clave:

Interacciones medicamentosas

Bases de datos

Evaluación de calidad

Full text is only available in PDF

References

[1.]

J.U. Rosholm, L. Bjerrum, J. Hallas, J. Worm, L.F. Gram.

Polypharmacy and the risk of drug-drug interactions among Danish elderly.

Danish Medical Bulletin, 45 (1998), pp. 210-213

Medline

[2.]

Estudio APEAS: estudio sobre la seguridad de los pacientes en Atención Primaria de Salud. Madrid: Ministerio de Sanidad y Consumo; 2008.

[3.]

J.M. Recalde, M.V. Zunzunegui, F. Beland.

Interacciones de fármacos prescritos en población mayor de 65 años.

Aten Primaria, 22 (1998), pp. 434-439

[4.]

R.J. Michocki, P.P. Lamy, F.J. Hooper, J.P. Richardson.

Drug prescribing for the elderly.

Arch Farm Med, 2 (1993), pp. 441-444

[5.]

National Prescribing Service. What is polypharmacy? NPS News n.° 13.2000.

[6.]

National Health Service. Medicines for older people. 2001. Department of Health [accessed, May 18, 2007]. Available from: http://www.gov.uk/nsf/olderpeople.htm

[7.]

A. Calvet, M. Díez de Ulzurrun, M.T. Pérez, J. Esteras.

Interacciones farmacológicas en tratamientos crónicos: medidas correctoras para su prevención en un área básica de salud rural.

Aten Primaria, 27 (2001), pp. 33-37

Medline

[8.]

T. Bermejo Viñedo, C. Pérez Menendez Conde.

Aplicación de las nuevas tecnologías a la farmacia hospitalaria en España.

Farm Hosp, 31 (2007), pp. 17-22

Medline

[9.]

V.L. Minh, G.M. McCart, C. Tsourounis.

An assessment of Free, online Drug-Drug Interaction Screening Programs (DSPs).

Hospital Pharmacy, 38 (2003), pp. 662-668

[10.]

J. Abarca, D.C. Malone, E.P. Armstrong, A.J. Grizzle, P.D. Hansten, R.C. van Bergen.

Concordance of severity ratings provided in tour drug interaction compendia.

J Am Pharm Assoc (Wash), 44 (2004), pp. 136-141

[11.]

Consejo General de Colegios Oficiales de Farmacéuticos. Base de Datos del Conocimiento farmacéutico BOT PLUS [accessed, May 17, 2007]. Available from: www.portalfarma.com

[12.]

XiZ Comunicacion. Medinteract [accessed, May 10, 2007]. Available from: www.medinteract.net

[13.]

Sociedad Española de Farmacia Hospitalaria. Guía de la SEFH [accessed, May 26, 2007]. Available from: www.sefh.es

[14.]

Lexi comp. Lexi-interact [accessed, May 18, 2007]. Available from: www.lexi.com

[15.]

Medscape, Drug Interaction Checker [accessed, May 19, 2007]. Available from: www.medscape.com

[16.]

P.D. Hansten, J.R. Horn.

Drug Interactions Analysis and Management.

Facts and Comparisons, (2007),

[17.]

Thomson Healthcare. Drug-reax [accessed, May 20, 2007]. Available from: www.micromedex.com

[18.]

I.H. Stockley.

Interacciones Farmacológicas.

2nd ed., Pharma Editores, (2006),

[19.]

D.S. Tatro.

Drug Interaction Facts.

Facts and Comparisons, (2007),

[20.]

K.A. Clauson, M.J. Seamon, A.S. Clauson, T.B. van.

Evaluation of drug information databases for personal digital assistans.

Am J Health-Syst Pharm, 61 (2004), pp. 1015-1023

[21.]

L. Galatti, G. Mazzaglia, A. Greco, E. Sessa, C. Cricelli, G.C. Schito, et al.

Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice.

Pharmacoepidemiol Drug Saf, 16 (2007), pp. 422-428

http://dx.doi.org/10.1002/pds.1389 | Medline

[22.]

N.L. Katende-Kyenda, M.S. Lubbe, J.H. Serfontein, I. Truter.

Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa.

Journal of the Medical Association of South Africa, 98 (2008), pp. 109-113

[23.]

W.M. Sweileh, A.F. Sawalha, N.A. Jaradat.

Extent of potential drug interactions among patients receiving anti-hypertensive medications.

Saudi Medical Journal, 26 (2005), pp. 548-552

Medline

[24.]

Grupo Ars XXI. Martindale [accessed, May 15, 2007]. Available from: www.imedicinas.com

[25.]

J. Peral Aguirregoitia, U. Lertxundi Etxebarria, M.J. Martínez Bengoechea, O. Mora Atorrasagasti, E. Franco Lamela, I. Gabilondo Zelaia.

Evaluación prospectiva de interacciones entre medicamentos en pacientes ingresados mediante una aplicación informática.

Farm Hosp, 31 (2007), pp. 99-100

[26.]

P. Amariles, N.A. Giraldo, M.J. Faus.

Interacciones medicamentosas: aproximación para establecer y evaluar su relevancia.

Med Clin (Barc), 129 (2007), pp. 27-35

[27.]

A. Rodríguez Terol, B. Santos Ramos, M.O. Caraballo Camacho, M. Ollero Baturone.

Relevancia clínica de las interacciones medicamentosas.

Med Clin (Barc), 130 (2008), pp. 758-759

[28.]

Agencia Española del Medicamento. AGEMED [accessed, May.25, 2007]. Available from: www.egemed.es

[29.]

American Society of Health-system pharmacy. American Hospital formulary Service Drug Information [accessed, May 23, 2007]. Available from: www.asph.org

[30.]

Drugdigest. Check Interaction [accessed, May 23, 2007]. Available from: www.drugdigest.org

[31.]

Drugmaster group. Druint software [accessed, May 23, 2007]. Available from: www.drugmastersl.com

[32.]

Drugs.com. Drug Interaction Checker [accessed, May 23, 2007]. Available from: www.drugs.com

[33.]

Epocrates [accessed, May 20, 2007]. Available from: www.epocrates.com

[34.]

Coordinadores de la Agencia española del medicamento y Productos Sanitarios. Guía de Prescripción Terapéutica [accessed, May 23, 2007]. Available from: www.imedicinas.com/GTPage/

[35.]

MedicinNet [accessed, May 27, 2007]. Available from: www.medicinenet.com

[36.]

Servicio Biblioteca Nacional de Medicina [accessed, May 25, 2007]. Available from: www.medlineplus.gov

[37.]

Dr. Koop [accessed, May 24, 2007]. Available from: www.drkoop.com

[38.]

RxList.inc. [accessed, May 23, 2007]. Available from: www.fdb.rxlist.com

[39.]

Grupo Ars XXI. Stockley Alertas; 2007

[40.]

The medical letter, inc. Adverse drug interaction program [accessed, May 22, 2007]. Available from: www.medicaletter.com

[41.]

Agence Française de Sécurité Sanitarie des Produits de Santé. Thesaurus des interactions Medicamenteus [accessed, May 23, 2007]. Available from: www.agemed.sante.gouv.fr

[42.]

Drug Bank [accessed, Jun 2, 2007]. Available from: www.drugbank.ca

[43.]

D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. Sto thard, et al.

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Res, 34 (2006), pp. D668-D672

http://dx.doi.org/10.1093/nar/gkj067 | Medline

[44.]

Drug Interaction Knowledge-base (DIKB) [accessed, May 24, 2007]. Available from: www.ieeexplore.ieee.org

[45.]

R.D. Boyce, C. Collins, J. Horn, I. Kalet.

Modeling drug mechanism knowledge using evidence and truth maintenance.

IEEE Trans Inf Technol Biomed, 11 (2007), pp. 386-397

Medline

[46.]

Drug Interaction Ontology [accessed, May 28, 2007]. Available from: www.bio.cs.titech.ac.jp

[47.]

S. Yoshikawa, K. Satou, A. Konagaya.

Drug interaction ontology (DIO) for inferences of possible drug-drug interactions.

Medinfo, 11 (2004), pp. 454-458

[48.]

FDA MedWatch database. Department of food and Human Services [accessed, May 26, 2007]. Available from: www.fda.gov

[49.]

N.L. Katende-Kyenda, M.S. Lubbe, J.H. Serfontein, I. Truter.

Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa.

Journal of the Medical Association of South Africa, 98 (2008), pp. 109-113

[50.]

General Practice Research Database (GPRD) [accessed, Jun 7, 2007]. Available from: www.gprd.com

[51.]

T.A. Hammad, D.J. Graham, J.A. Staffa, C.J. Kornegay, G.J. Dal Pan.

Onset of acute myocardial infarction after use of non-steroidal antiinflammatory drugs.

Pharmacoepidemiol Drug Saf, 17 (2008), pp. 315-321

http://dx.doi.org/10.1002/pds.1560 | Medline

[52.]

Y. Yang, E. Moir, G. Kontopidis, P. Taylor, M.A. Wear, K. Malone, et al.

Structure-based discovery of a family of synthetic cyclophilin inhibitors showing a cyclosporin-A phenotype in CaenorhaBDIMtis elegans.

Biochem Biophys Res Commun, 363 (2007), pp. 1013-1019

http://dx.doi.org/10.1016/j.bbrc.2007.09.079 | Medline

[53.]

M&T Drug Interaction Database. Department of pharmaceutics. University of Washington [accessed, Jun 5, 2007]. Available from: www.druginteractioninfo.org

[54.]

I. Ragueneau-Majlessi, X. Boulenc, C. Rauch, H. Hachad, R.H. Levy.

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Curr Drug Metab, 8 (2007), pp. 810-814

Medline

[55.]

RAD-AR Council. Anti-hypertensive drug database [accessed, May 25, 2007]. Available from: www.rad-ar.ogr.jp

[56.]

M. Yoshida, T. Matsumoto, T. Suzuki, S. Kitamura, T. Mayama.

Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker.

Pharmacoepidemiol Drug Saf, 17 (2008), pp. 70-71

http://dx.doi.org/10.1002/pds.1480 | Medline

[57.]

Side Effects software [accessed, May 26, 2007]. Available from: www.sidefx.com

[58.]

G.N. Fox.

Drug interactions software programs.

J Fam Pract, 33 (1991), pp. 273-280

Medline

[59.]

STICH [accessed, May 27, 2007]. Available from: www.stitch.embl.de

[60.]

M. Kuhn, C. von Mering, M. Campillos, L.J. Jensen, P. Bork.

STITCH: interaction networks of chemicals and proteins.

Nucleic Acids Res, 36 (2008), pp. D684-D688

http://dx.doi.org/10.1093/nar/gkm795 | Medline

[61.]

The marine natural products database (MNPD) [accessed, May 27, 2007]. Available from: www.dmnp.chemnetbase.com

[62.]

B. Liu, J. Zhou.

SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.

J Comput Chem, 26 (2005), pp. 484-490

http://dx.doi.org/10.1002/jcc.20186 | Medline

[63.]

The traditional Chinese medicines database (TCMD) [accessed, May 30, 2007]. Available from: www.gfmer.ch

[64.]

Veteran Health Administration (VHA) clinical database. Department of Veterans Affairs [accessed, May 20, 2007]. Available from: www.va.gov

[65.]

D.D. French, C.E. Margo.

Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alphablockers.

Drug Saf, 31 (2008), pp. 241-247

Medline

[66.]

B. Janchawee, W. Wongpoowarak, T. Owatranporn, V. Chongsuvivatwong.

Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand.

J Clin Pharm Ther, 30 (2005), pp. 13-20

http://dx.doi.org/10.1111/j.1365-2710.2004.00598.x | Medline

[67.]

British National Formulary. BNF Group [accessed, Jul 30, 2007]. Available from: www.bnf.org

[68.]

N. Tavassoli, A. Sommet, M. Lapeyre-Mestre, H. Bagheri, J.L. Montrastruc.

Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).

Drug Saf, 30 (2007), pp. 1063-1071

Medline

[69.]

K.S. Mellbye, C. Berg.

Heavy consumers of drugs-seen from the viewpoint of the community pharmacist.

Tidsskr Nor Laegeforen, 124 (2004), pp. 3069-3071

Medline

[70.]

E.W. Nielsen, K. Dybwik.

Drug interactions in an intensive care unit.

Tidsskr Nor Laegeforen, 124 (2004), pp. 2907-2908

Medline

[71.]

L. Guedon-Moreau, D. Ducrocq, M.F. Duc, Y. Quieureux, C. L’Hote, J. Deligne, et al.

Absolute contraindications in relation to potencial drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

Eur J Clin Pharmacol, 59 (2003), pp. 689-695

[72.]

L. Galatti, G. Mazzaglia, A. Greco, E. Sessa, C. Cricelli, G.C. Schito, et al.

Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice.

Pharmacoepidemiol Drug Saf, 16 (2007), pp. 422-428

http://dx.doi.org/10.1002/pds.1389 | Medline

[73.]

G. Trifiro, S. Corrao, M. Alacqua, S. Moretti, M. Tari, A.P. Caputi, et al.

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Br J Clin Pharmacol, 62 (2006), pp. 582-590

http://dx.doi.org/10.1111/j.1365-2125.2006.02687.x | Medline

[74.]

C.M. Hohl, J. Dankoff, A. Colacone, M. Afilalo.

Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department.

Ann Emerg Med, 38 (2001), pp. 666-671

http://dx.doi.org/10.1067/mem.2001.119456 | Medline

[75.]

F. Vroom, E.N. van Roon, P.B. van den Berg, J.R. Brouwers, L.T. de Jongvan den Berg.

Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy-a descriptive study.

Pharmacoepidemiol Drug Saf, 17 (2008), pp. 52-61

http://dx.doi.org/10.1002/pds.1506 | Medline

[76.]

Walgreens.com [accessed, May 28, 2007]. Available from: www.walgreens.com

[77.]

A2Z Drugs [accessed, Jun 3, 2007]. Available from: www.az2drugs.com

[78.]

K.A. Clauson, M.J. Seamon, A.S. Clauson, T.B. van.

Evaluation of drug information databases for personal digital assistants.

Am J Health Syst Pharm, 61 (2004), pp. 1015-1024

[79.]

Clinical Pharmacology on hand [accessed, Jun 2, 2007]. Available from: www.cponhand.gsm.com

[80.]

PDR. Drug Interaction [accessed, May 25, 2007]. Available from: www.pdr.net

[81.]

Tarascon Pocket Pharmacopoeia [accessed, May 25, 2007]. Available from: www.tarascon.com

[82.]

Triple Prescribing Guide [accessed, Jun 3, 2007]. Available from: www.pharmscope.com

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter